Monday, September 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Johnson Controls Second Quarter Performance Comparison

Elaine Mendonca by Elaine Mendonca
January 30, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Johnson Controls is projecting that its second-quarter organic revenue will remain relatively unchanged compared to the previous year. The company also expects its adjusted earnings per share (EPS) before special items to be in the range of $0.74 to $0.78, slightly lower than the estimated $0.78.

During the first quarter of 2024, Johnson Controls reported an adjusted EPS of $0.51, which met market expectations. This indicates a steady performance in line with projections.

In the second quarter of 2023, the company experienced a significant 13% growth in organic sales and a 19% increase in adjusted EPS, reaching $0.75. This demonstrates a strong performance compared to the previous year.

Considering the company’s performance in the corresponding quarters of 2024 and 2023, it provides valuable context for understanding its expectations for the second quarter of this year.

Johnson Controls International plc (JCI) Stock Prices Show Mixed Performance on January 30, 2024: Conduct Thorough Research and Analysis Before Investing

On January 30, 2024, Johnson Controls International plc (JCI) experienced a mixed performance in its stock prices. As of that date, JCI was trading in the middle of its 52-week range, indicating stability. However, it was below its 200-day simple moving average, suggesting a bearish sentiment. The price of JCI shares increased by $0.06 since the market last closed, representing a rise of 0.11%. The stock closed at $56.65. In pre-market trading, JCI experienced a drop of $1.24 in its stock price. Investors should conduct thorough research and analysis before making any investment decisions regarding JCI or any other stock.

JCI Stock Performance on January 30, 2024: Mixed Revenue Growth and Earnings Decline Analysis

Title: JCI Stock Performance on January 30, 2024: A Mixed Bag of Revenue Growth and Earnings Decline

Introduction:

On January 30, 2024, Johnson Controls International (JCI) witnessed a mixed performance in terms of its stock performance. This article will delve into JCI’s financial data, focusing on its revenue growth and earnings decline, to provide insights into the stock’s performance on January 30, 2024.

Total Revenue Growth:

JCI reported a total revenue of $26.79 billion for the past year, representing a 5.91% increase compared to the previous year. However, the total revenue remained flat in the fourth quarter of 2023, standing at $6.91 billion.

Net Income Performance:

JCI recorded a net income of $1.85 billion over the past year, reflecting a significant 20.69% increase compared to the previous year. However, similar to the total revenue, JCI’s net income remained flat in the fourth quarter of 2023, amounting to $549.00 million.

Earnings per Share Decline:

JCI’s EPS for the past year was reported at $2.69, indicating a substantial 22.83% increase compared to the previous year. However, JCI experienced a notable decline in EPS during the fourth quarter of 2023, with the figure dropping to $0.80.

Conclusion:

JCI’s stock performance on January 30, 2024, was characterized by a mixed bag of revenue growth and earnings decline. The lack of growth in the fourth quarter raised concerns among investors. Additionally, the decline in EPS during the same period may have further impacted investor sentiment. Investors and analysts will closely monitor JCI’s future financial reports to gauge the company’s ability to sustain revenue growth and improve its earnings performance.

Tags: JCI
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Real Estate Investment Markets and money

Mixed Analyst Sentiments and Price Targets for SL Green Realty

Biotechnology Market Capitalization

CanFite Expands Licensing Agreement to Include Pancreatic Cancer Indication

Finance_Fiscal (2)

Morgan Stanley Analyst Upgrades Price Target for Regions Financial

Recommended

Emergent BioSolutions Stock

A Tale of Two Realities: Emergent BioSolutions’ Social Mission and Financial Strain

4 weeks ago
Food Retailers Stock Bull Market

JP Morgan Analyst Maintains Neutral Rating on Tyson Foods with Revised Price Target

2 years ago
MMM stock news

Bearish Sentiment Surrounds Air Lease NYSE AL Trading

2 years ago
QuantumScape Stock

QuantumScape Leadership Executes Major Stock Sales, Raising Investor Concerns

5 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Ubiquiti Shares Reach New Heights on Product Expansion Momentum

BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

Leadership Crisis at Nestlé Sparks Investor Concerns

Standex Shares Plunge Amid Technical Warnings and Insider Selling

Navigating Credit Headwinds: Synchrony’s Strategic Expansion Amid Sector Challenges

Tech Sector Surge: AI and Cloud Computing Fuel Vanguard ETF’s Record Run

Trending

Pfizer Stock
Healthcare

Pfizer’s Strategic Gambit: A $7.3 Billion Entry into the Weight-Loss Arena

by Dieter Jaworski
September 22, 2025
0

In a move signaling its serious intent to capture a share of the lucrative anti-obesity drug market,...

Nike Stock

Nike Shares Face Critical Earnings Test

September 22, 2025
Tutor Perini Stock

Insider Sales at Tutor Perini Coincide with Stock Peak

September 22, 2025
Ubiquiti Stock

Ubiquiti Shares Reach New Heights on Product Expansion Momentum

September 22, 2025
BioNTech Stock

BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

September 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pfizer’s Strategic Gambit: A $7.3 Billion Entry into the Weight-Loss Arena
  • Nike Shares Face Critical Earnings Test
  • Insider Sales at Tutor Perini Coincide with Stock Peak

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com